| Literature DB >> 26064171 |
İlhan Öztekin1, Hakan Akdere2, Nuray Can3, Tevfik Aktoz2, Ersan Arda2, Fatma Nesrin Turan4.
Abstract
This research aimed to compare anti-inflammatory effects of oligonol, acupuncture, and quantum light therapy in rat models of estrogen-induced prostatitis. Adult male Wistar albino rats were grouped as follows: Group I, control (n = 10); Group II, chronic prostatitis (n = 10); Group III, oligonol (n = 10); Group IV, acupuncture (n = 10); Group V, quantum (n = 10); Group VI, oligonol plus quantum (n = 10); Group VII, acupuncture plus oligonol (n = 10); Group VIII, quantum plus acupuncture (n = 10); and Group IX, acupuncture plus quantum plus oligonol (n = 10). Chronic prostatitis (CP) was induced by the administration of 17-beta-estradiol (E2) and dihydrotestosterone (DHT). Oligonol was given for 6 weeks at a dose of 60 mg/day. Acupuncture needles were inserted at CV 3/4 and bilaterally B 32/35 points with 1-hour manual stimulation. Quantum therapy was administered in 5-minute sessions three times weekly for 6 weeks. Lateral lobes of prostates were dissected for histopathologic evaluation. Although all of the treatment modalities tested in this study showed anti-inflammatory effects in the treatment of CP in male rats, a synergistic effect was observed for oligonol plus quantum light combination. Monotherapy with oligonol showed a superior anti-inflammatory efficacy as compared to quantum light and acupuncture monotherapies.Entities:
Year: 2015 PMID: 26064171 PMCID: PMC4433713 DOI: 10.1155/2015/687196
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Structure of the experiment.
| Groups |
| Drug treatment | Agents administrated to induce inflammation | |
|---|---|---|---|---|
| Group I | Normal control | 10 | — | — |
| Group II | Chronic prostatitis | 10 | — | E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group III | Oligonol | 9 | Oligonol 60 mg/kg (p.o.) | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group IV | Acupuncture | 7 | — | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group V | Quantum | 7 | — | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group VI | Oligonol + quantum | 8 | Oligonol 60 mg/kg (p.o.) | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group VII | Acupuncture + oligonol | 9 | Oligonol 60 mg/kg (p.o.) | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group VIII | Quantum + acupuncture | 8 | — | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
| Group IX | Quantum + oligonol + acupuncture | 9 | Oligonol 60 mg/kg (p.o.) | 10 E2 0.25 mg/kg (s.c.) + DHT 0.25 mg/kg (s.c.) |
E2, 17-beta-estradiol; DHT, dihydrotestosterone; s.c., subcutaneous injection; p.o., oral administration.
Parameters of the quantum light therapy used.
| Wavelength of impulsive infrared laser radiation: 890–910 nanometers | |
| Wavelength of pulsating broadband infrared radiation: 860–960 nanometers | |
| Wavelength of pulsating broadband red radiation: 40–740 nanometers | |
| Frequency setting: 50 Hz | |
| Frequency of red light radiation: 2 Hz | |
| Magnetic induction: 35 ± 10 mTl | |
| Time of radiation: 5 min. | |
| Power supply: alternating current | |
| Frequency: 50/60 Hz | |
| Power consumed from an electric network: 20 W | |
| Power: 12 W emitter and 30 W emitter (perineum) | |
| Beam area at the skin: 4 cm2 | |
| Anatomical location: suprapubic, urinary bladder, anterior penile, and femoral artery (bilateral) | |
| regions and mid-perineum region between testicles and anus (including prostate area) | |
| Number of treatments: 18 procedures | |
| Interval between treatments: 3 days a week for a total duration of 6 weeks |
Figure 1Histological views of prostatic inflammation in all groups. Normal controls; Group I, (hematoxylin and eosin, ×100) (a); Group II, chronic prostatitis (hematoxylin and eosin, ×100) (b); Group III, oligonol (hematoxylin and eosin, ×100) (c); Group IV, acupuncture (hematoxylin and eosin, ×100) (d); Group V, quantum (hematoxylin and eosin, ×200) (e); Group VI, oligonol plus quantum (hematoxylin and eosin, ×100) (f); Group VII, acupuncture plus oligonol (hematoxylin and eosin, ×200) (g); Group VIII, quantum plus acupuncture (hematoxylin and eosin, ×100) (h); Group IX, acupuncture plus quantum plus oligonol (hematoxylin and eosin, ×200) (i).
Figure 2Histological views of prostatic inflammation. Control group without any inflammation, grade 0 (hematoxylin and eosin, ×100) (a). Some contact between epithelial cells and inflammatory cells (black arrow), grade 1 (hematoxylin and eosin, ×100) (b). Periglandular infiltrates adjacent to partially destroyed epithelium (black arrows), grade 2 (hematoxylin and eosin, ×100) (c). The inflammation was intensive (black arrow) and the number of inflamed acini was more than 25%, grade 3 (hematoxylin and eosin, ×100) (d).
Body weight, prostate weight, and prostatitis score of the groups.
| BW day 1 (gr) | BW day 20 (gr) | BW day 40 (gr) | Prostate weight (mg) | Prostatitis score | ||
|---|---|---|---|---|---|---|
| Groups | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Median | |
| Median | Median | Median | Median | |||
| Group I | Normal control ( | 314.40 ± 20.57 | 371.00 ± 29.06 | 412.60 ± 16.44 | 1,046.80 ± 61.08 | 1 (0–2) |
| 312.50 (289–350) | 364.00 (325–408) | 419.50 (380–430) | 1,030.50 (979–1130) | |||
|
| ||||||
| Group II | Chronic prostatitis ( | 311.80 ± 15.29 | 345.20 ± 27.98 | 367.80 ± 35.89 | 950.00 ± 25.98 | 2 (1–3) |
| 317.00 (287–330) | 342.50 (315–392) | 373.00 (321–420) | 950.50 (920–985) | |||
|
| ||||||
| Group III | Oligonol ( | 319.67 ± 10.44 | 362.78 ± 23.02 | 380.33 ± 14.47 | 964.00 ± 17.41 | 1 (1-2) |
| 324.00 (302–330) | 373.00 (322–378) | 385.00 (354–394) | 974.00 (939–980) | |||
|
| ||||||
| Group IV | Acupuncture ( | 316.86 ± 15.04 | 372.43 ± 23.41 | 406.71 ± 14.04 | 947.86 ± 28.75 | 2 (1-2) |
| 321.00 (294–332) | 381.00 (335–394) | 409.00 (390–425) | 934.00 (926–992) | |||
|
| ||||||
| Group V | Quantum ( | 310.00 ± 14.00 | 341.86 ± 29.01 | 381.43 ± 25.25 | 942.71 ± 2.09 | 1 (1–3) |
| 308.00 (294–331) | 326.00 (321–389) | 384.00 (350–417) | 935.00 (928–991) | |||
|
| ||||||
| Group VI | Oligonol + quantum ( | 313.50 ± 9.77 | 344.12 ± 19.74 | 383.88 ± 14.15 | 950.25 ± 19.61 | 1 (1-2) |
| 314.00 (298–325) | 343.00 (323–386) | 388.00 (368–417) | 945.00 (928–975) | |||
|
| ||||||
| Group VII | Acupuncture + oligonol ( | 311.22 ± 8.87 | 349.22 ± 27.79 | 380.11 ± 13.82 | 940.78 ± 8.03 | 1 (1–3) |
| 309.00 (301–326) | 331.00 (323–387) | 372.00 (364–399) | 940.00 (930–953) | |||
|
| ||||||
| Group VIII | Quantum + acupuncture ( | 308.88 ± 9.43 | 358.75 ± 27.35 | 386.00 ± 21.82 | 956.38 ± 25.15 | 2 (1–3) |
| 307.50 (294–321) | 356.00 (329–392) | 380.50 (358–416) | 939.50 (935–989) | |||
|
| ||||||
| Group IX | Quantum + oligonol + acupuncture | 312.44 ± 14.40 | 367.67 ± 32.35 | 388.33 ± 15.50 | 953.56 ± 17.27 | 1 (1–3) |
SD: standard deviation; median (min–max): (minimum–maximum) values; BW: body weight; gr: gram; mg: milligram.
Figure 3Prostate weight groups on day 40.